|By PR Newswire||
|October 17, 2007 06:06 PM EDT||
SAN FRANCISCO, Oct. 17 /PRNewswire/ -- Collaborative Drug Discovery, Inc. (CDD, Inc.) has captured extensive literature data from six years of recent publications focused on the fight against Chagas' disease. Now for the first time these data are available to researchers free of charge, via the CDD Database.
Sources include the Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry, the Journal of American Chemical Society, Journal of Ethnopharmacology, Proceedings of the National Academy of Sciences (PNAS), International Journal of Antimicrobial Agents, Bioorganic & Medicinal Chemistry Letters, European Journal of Medicinal Chemistry, Molecular and Biochemical Parasitology, Journal of Inorganic Biochemistry, Acta Topical, and Experimental Parasitology.
The data sets captured include 574 compound structures and just over 350 different enzyme, cell, animal, and toxicity based protocols. The data are conveniently organized so scientists can easily mine for hits, sub-structural motifs or keywords and obtain the original literature reference for more detailed analysis.
These data sets will help researchers better prioritize compounds to test experimentally and build superior models to guide experiments.
This project is the first of a series literature data capture projects focused on drug discovery research into neglected infectious diseases. In addition to literature data, community members also provide open access to some of their experimental results either pre- or post-publication. The CDD global community includes leading researchers from four continents.
To submit other datasets, capabilities, expertise, or models which would be valuable to the Chagas' or neglected disease community, please contact us at [email protected].
A significant subset of all the community data -- and a range of other data sets such as Chagas' data -- is available openly to the public at no cost. For this historical set of data either visit http://www.collaborativedrug.com/registrations/new or e-mail [email protected] to register for the username and password to the open data sets.
About Collaborative Drug Discovery: CDD is the world's first platform for selectively sharing collaborative drug discovery data. Scientists working with the CDD community platform can pool their research in order to more effectively develop new drug candidates for commercial and humanitarian markets. Conceived in 2003, and formally launched in 2004, Collaborative Drug Discovery (CDD) has been serving the collaborative data needs of researchers for years. The CDD global community includes hundreds of scientists from leading research foundations, academia and industry. A subset of the data is available openly to the public at no cost. For more information, please visit http://www.collaborativedrug.com/.Collaborative Drug Discovery, Inc.
CONTACT: Barry A. Bunin, PhD, President of Collaborative Drug Discovery,
Inc., +1-650-204-3084, [email protected]
Feb. 27, 2017 06:00 AM EST Reads: 6,144
Feb. 27, 2017 05:00 AM EST Reads: 7,403
Feb. 27, 2017 04:30 AM EST Reads: 2,227
Feb. 27, 2017 04:30 AM EST Reads: 4,290
Feb. 27, 2017 04:00 AM EST Reads: 7,338
Feb. 27, 2017 03:30 AM EST Reads: 2,195
Feb. 27, 2017 03:00 AM EST Reads: 2,285
Feb. 27, 2017 03:00 AM EST Reads: 2,479
Feb. 27, 2017 02:00 AM EST Reads: 7,547
Feb. 27, 2017 01:30 AM EST Reads: 1,949
Feb. 27, 2017 01:15 AM EST Reads: 1,711
Feb. 27, 2017 01:15 AM EST Reads: 1,680
As businesses adopt functionalities in cloud computing, it’s imperative that IT operations consistently ensure cloud systems work correctly – all of the time, and to their best capabilities. In his session at @BigDataExpo, Bernd Harzog, CEO and founder of OpsDataStore, will present an industry answer to the common question, “Are you running IT operations as efficiently and as cost effectively as you need to?” He will expound on the industry issues he frequently came up against as an analyst, and...
Feb. 27, 2017 01:00 AM EST Reads: 2,146
Feb. 27, 2017 01:00 AM EST Reads: 1,360
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
Feb. 27, 2017 12:30 AM EST Reads: 8,843